Du, Yu

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 1,174

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 423

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.

Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 316

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine

Liver Disease Diagnosis and TreatmentPharmacology and Obesity Treatment

Cited by 315

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 202

Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist

Benichou, O., Coskun, T., Gonciarz, M. D., Garhyan, P., Adams, A. C., Du, Y., Dunbar, J. D., Martin, J. A., Mather, K. J., Pickard, R. T., et al. (2023) · Cell Metabolism

Regulation of Appetite and ObesityGDF15 and Related Biomarkers

Cited by 115

The novel GIP , GLP ‐1 and glucagon receptor agonist retatrutide delays gastric emptying

Urva, S., O'Farrell, L., Du, Y., Loh, M. T., Hemmingway, A., Qu, H., Alsina‐Fernandez, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023) · Diabetes, Obesity and Metabolism

Gastrointestinal motility and disordersDiabetes Treatment and Management

Cited by 28

754-P: Effect of Retatrutide on Kidney Parameters in People with Type 2 Diabetes and/or Obesity—A Post-Hoc Analysis of Two Phase 2 Trials

HEERSPINK, H. L., LU, Z., DU, Y., DUFFIN, K. L., COSKUN, T., HAUPT, A., & HARTMAN, M. L. (2024) · Diabetes

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 7